WNT5A and pulmonary arterial hypertension: Kang et al. found that Ponatinib, a multi-target tyrosine kinase inhibitor, decreased the expression of Wnt5a, β-catenin, and Cyclin D in hypoxic human PASMCs, improving vascular remodeling and slowing disease progression in bleomycin-induced PAH rat models.445 Currently, most PH treatments targeting the Wnt signaling pathway focus on inhibiting the canonical pathway.